Style | Citing Format |
---|---|
MLA | Barzegar M, et al.. "Prevalence and Incidence of Multiple Sclerosis in Isfahan, Iran Between 1996 and 2021: A Population-Based Study." Multiple Sclerosis and Related Disorders, vol. 84, no. , 2024, pp. -. |
APA | Barzegar M, Vaheb S, Mirmosayyeb O, Ashtari F, Afsharisafavi A, Adibi I, Shaygannejad A, Mazaheri S, Rahimi M, Shaygannejad V (2024). Prevalence and Incidence of Multiple Sclerosis in Isfahan, Iran Between 1996 and 2021: A Population-Based Study. Multiple Sclerosis and Related Disorders, 84(), -. |
Chicago | Barzegar M, Vaheb S, Mirmosayyeb O, Ashtari F, Afsharisafavi A, Adibi I, Shaygannejad A, Mazaheri S, Rahimi M, Shaygannejad V. "Prevalence and Incidence of Multiple Sclerosis in Isfahan, Iran Between 1996 and 2021: A Population-Based Study." Multiple Sclerosis and Related Disorders 84, no. (2024): -. |
Harvard | Barzegar M et al. (2024) 'Prevalence and Incidence of Multiple Sclerosis in Isfahan, Iran Between 1996 and 2021: A Population-Based Study', Multiple Sclerosis and Related Disorders, 84(), pp. -. |
Vancouver | Barzegar M, Vaheb S, Mirmosayyeb O, Ashtari F, Afsharisafavi A, Adibi I, et al.. Prevalence and Incidence of Multiple Sclerosis in Isfahan, Iran Between 1996 and 2021: A Population-Based Study. Multiple Sclerosis and Related Disorders. 2024;84():-. |
BibTex | @article{ author = {Barzegar M and Vaheb S and Mirmosayyeb O and Ashtari F and Afsharisafavi A and Adibi I and Shaygannejad A and Mazaheri S and Rahimi M and Shaygannejad V}, title = {Prevalence and Incidence of Multiple Sclerosis in Isfahan, Iran Between 1996 and 2021: A Population-Based Study}, journal = {Multiple Sclerosis and Related Disorders}, volume = {84}, number = {}, pages = {-}, year = {2024} } |
RIS | TY - JOUR AU - Barzegar M AU - Vaheb S AU - Mirmosayyeb O AU - Ashtari F AU - Afsharisafavi A AU - Adibi I AU - Shaygannejad A AU - Mazaheri S AU - Rahimi M AU - Shaygannejad V TI - Prevalence and Incidence of Multiple Sclerosis in Isfahan, Iran Between 1996 and 2021: A Population-Based Study JO - Multiple Sclerosis and Related Disorders VL - 84 IS - SP - EP - PY - 2024 ER - |